BMJ Open (Feb 2023)

Four 2×2 factorial trials of smartphone CBT to reduce subthreshold depression and to prevent new depressive episodes among adults in the community–RESiLIENT trial (Resilience Enhancement with Smartphone in LIving ENvironmenTs): a master protocol

  • Toshi A Furukawa,
  • Tatsuo Akechi,
  • Masaru Horikoshi,
  • Yan Luo,
  • Hisashi Noma,
  • Takeo Nakayama,
  • Helen Christensen,
  • Naoki Kondo,
  • Norito Kawakami,
  • Aran Tajika,
  • Ronald C Kessler,
  • Shingo Fukuma,
  • Masatsugu Sakata,
  • Rie Toyomoto,
  • James M S Wason

DOI
https://doi.org/10.1136/bmjopen-2022-067850
Journal volume & issue
Vol. 13, no. 2

Abstract

Read online

Introduction The health burden due to depression is ever increasing in the world. Prevention is a key to reducing this burden. Guided internet cognitive–behavioural therapies (iCBT) appear promising but there is room for improvement because we do not yet know which of various iCBT skills are more efficacious than others, and for whom. In addition, there has been no platform for iCBT that can accommodate ongoing evolution of internet technologies.Methods and analysis Based on our decade-long experiences in developing smartphone CBT apps and examining them in randomised controlled trials, we have developed the Resilience Training App Version 2. This app now covers five CBT skills: cognitive restructuring, behavioural activation, problem-solving, assertion training and behaviour therapy for insomnia. The current study is designed as a master protocol including four 2×2 factorial trials using this app (1) to elucidate specific efficacies of each CBT skill, (2) to identify participants’ characteristics that enable matching between skills and individuals, and (3) to allow future inclusion of new skills. We will recruit 3520 participants with subthreshold depression and ca 1700 participants without subthreshold depression, to examine the short-term efficacies of CBT skills to reduce depressive symptoms in the former and to explore the long-term efficacies in preventing depression in the total sample. The primary outcome for the short-term efficacies is the change in depressive symptoms as measured with the Patient Health Questionnaire-9 at week 6, and that for the long-term efficacies is the incidence of major depressive episodes as assessed by the computerised Composite International Diagnostic Interview by week 50.Ethics and dissemination The trial has been approved by the Ethics Committee of Kyoto University Graduate School of Medicine (C1556).Trial registration number UMIN000047124.